For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Alpha Cognition Inc. (ACOG) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Alpha Cognition Inc. is a member of our Medical group, which includes 989 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the st ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this vaccine maker have returned -10.9%, compared to the Zacks S&P 500 composite's +5.2% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Novavax falls in, has gained 0.9%. The key question now is: What could be the stock's future di ...

Ginkgo Bioworks Holdings, Inc. (DNA) shares rallied 18.9% in the last trading session to close at $11.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 36.1% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the potential of Ginkgo’s proprietary cell programming platforms, Foundry and Codebase. The company offers R&D services ut ...

In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.09, marking a -1.42% move from the previous day. This change lagged the S&P 500's daily gain of 0.52%. Meanwhile, the Dow gained 0.63%, and the Nasdaq, a tech-heavy index, added 0.48%. Prior to today's trading, shares of the company had lost 20.6% lagged the Medical sector's gain of 1.88% and the S&P 500's gain of 4.27%.Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings discl ...

Company Performance - Adma Biologics closed at $18.16, reflecting a -1.3% change from the previous day, underperforming the S&P 500's gain of 0.52% [1] - The stock has decreased by 6.93% over the past month, while the Medical sector gained 3.5% and the S&P 500 increased by 5.95% [1] Upcoming Earnings - Adma Biologics is projected to report earnings of $0.14 per share, indicating a year-over-year growth of 7.69% [2] - The Zacks Consensus Estimate for revenue is $121.1 million, representing a 12.98% increase from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $0.61 per share and revenue at $505.8 million, showing increases of +24.49% and +18.61% respectively from the prior year [3] - Recent changes in analyst estimates reflect shifting business dynamics, with positive adjustments indicating optimism regarding business and profitability [3] Valuation Metrics - Adma Biologics has a Forward P/E ratio of 30.16, compared to the industry average of 19.05, suggesting it is trading at a premium [6] - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a current Zacks Industry Rank of 83 [6] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks delivering an average annual return of +25% since 1988 [5] - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a recent 8.27% decrease in the Consensus EPS estimate over the last 30 days [5]

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $5.03, down 6.85% from the previous trading session, underperforming the S&P 500's daily gain of 0.52% [1] - Over the past month, the stock has appreciated by 21.35%, outperforming the Medical sector's gain of 3.5% and the S&P 500's gain of 5.95% [1] Upcoming Earnings - The company is expected to report an EPS of -$0.34, which is a 15% increase from the prior-year quarter [2] - Quarterly revenue is projected to be $15.58 million, reflecting an 8.02% increase from the year-ago period [2] Full Year Estimates - For the full year, earnings are projected at -$1.34 per share and revenue at $74.95 million, showing increases of 20.71% and 27.38% respectively from the previous year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Recursion Pharmaceuticals are important as they indicate evolving short-term business trends [4] - Positive changes in estimates suggest analyst optimism regarding the company's business and profitability [4] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record of outperforming, with 1 rated stocks producing an average annual return of +25% since 1988 [6] - The Zacks Consensus EPS estimate for Recursion Pharmaceuticals has shifted 0.19% upward over the past month, and the company currently holds a Zacks Rank of 3 (Hold) [6] Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CVS Health (CVS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.CVS Health is a member of our Medical group, which includes 996 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 1 ...

Moderna (MRNA) ended the recent trading session at $27.54, demonstrating a +2.53% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.8%. Meanwhile, the Dow gained 0.94%, and the Nasdaq, a tech-heavy index, added 0.97%. Coming into today, shares of the biotechnology company had gained 3.11% in the past month. In that same time, the Medical sector gained 3.12%, while the S&P 500 gained 5.12%. Analysts and investors alike will be keeping a close ey ...

Adaptive Biotechnologies (ADPT) shares soared 12.5% in the last trading session to close at $11.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.5% gain over the past four weeks.The sudden rise in price can be attributed to investor optimism related to growing demand and volume growth of Adaptive Biotechnologies’ clonoSEQ, an FDA-cleared diagnostic test used to detect and monitor minimal residual disease (MRD) in patients w ...

Krystal Biotech, Inc. (KRYS) shares soared 4.2% in the last trading session to close at $143.67. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.3% gain over the past four weeks.The stock price gain was observed after Krystal Biotech initiated dosing patients in its phase III IOLITE study of KB803 eye drops for DEB-related corneal damage. As a next-generation version of its approved gene therapy, Vyjuvek, KB803 targets a rare ...